The bioactive sphingolipid ceramide impacts diverse cellular processes (e.g., apoptosis and cell proliferation) through its effects on membrane dynamics and intracellular signalling pathways. The dysregulation of ceramide metabolism has been implicated in cancer evasion of apoptosis and targeting ceramide metabolism has potential therapeutic benefits as a strategy to kill cancer cells and slow tumor growth. However, the mechanisms of cancer cell resistance to ceramide-mediated cell death are vastly intertwined and incompletely understood. To shed light on this mystery, we performed a genome wide CRISPR-Cas9 screen to systematically identify regulators of cancer resistance to the soluble short chain ceramide, C6 ceramide (C6-Cer). Our results reveal a complex landscape of genetic modifiers of C6-Cer toxicity, including genes associated with ceramide and sphingolipid metabolism, vesicular trafficking, and membrane biology. Furthermore, we find that loss of the phospholipid flippase subunit TMEM30A impairs the plasma membrane trafficking of its binding partner, the P4-type ATPase ATP11B, and depletion of TMEM30A or ATP11B disrupts plasma membrane asymmetry and promotes resistance to C6-Cer toxicity. Together, our findings provide a resource of genetic modifiers of C6-Cer toxicity and reveal an unexpected role of plasma membrane asymmetry in C6-Cer induced cell death.
A genome-wide CRISPR screen implicates plasma membrane asymmetry in exogenous C6-ceramide toxicity
- Award Group:
- Funder(s): National Institutes of Health
- Award Id(s): R01GM112948
- Funder(s):
- Award Group:
- Funder(s): American Cancer Society
- Award Id(s): RSG-19-192-01
- Funder(s):
Currently Viewing Accepted Manuscript - Newer Version Available
- Split-screen
- Views Icon Views
- Open the PDF for in another window
-
Article Versions Icon
Versions
- Version of Record 19 December 2022
- Accepted Manuscript 21 November 2022
- Share Icon Share
-
Tools Icon
Tools
- Search Site
Siti Nur Sarah Morris, Kirandeep K. Deol, Mike Lange, James A. Olzmann; A genome-wide CRISPR screen implicates plasma membrane asymmetry in exogenous C6-ceramide toxicity. Biol Open 2022; bio.059695. doi: https://doi.org/10.1242/bio.059695
Download citation file:
Advertisement
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Biology Open 2023 - a year in review
In this Editorial, BiO Editor-in-Chief Dan Gorelick reviews the journal's performance in 2023 and discusses his plans to improve author experience.
The Forest of Biologists
Our Publisher Claire Moulton recently visited the two Woodland Trust UK sites where we are planting new native trees for published Research and Review papers and protecting ancient woodland on behalf of our peer reviewers.
A Year at the Forefront
This series of Review articles aims to highlight the key discoveries, technological innovations, new resources and new hypotheses that have made an impact in a specific biological field during the past year. This publishing opportunity is available to early-career researchers, without a publication charge. Find out about eligibility and how to submit a proposal.
How we support early-career researchers
Biology Open, its sister journals and its not-for-profit publisher, The Company of Biologists, support early-career researchers in numerous ways, helping them grow their network and raise their profile. Find out what we can do to support you.